Antiplatelet therapy to prevent cardiovascular events and mortality in patients with intermittent claudication.

Peng Foo Wong, Lee-Yee Chong, Gerard Stansby

Department of Vascular Surgery, James Cook University Hospital, Marton Road, Middlesbrough, Cleveland, TS4 3BW England. pwong23@hotmail.com

JAMA : the journal of the American Medical Association 2013 Mar 6

filter terms:

Do antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antiplatelet is most strongly associated with a reduced risk of all-cause and CVD mortality? In patients with intermittent claudication, antiplatelet therapies are associated with lower all-cause and CVD mortality compared with placebo. Compared with all antiplatelet therapies, the strongest evidence exists for thienopyridines, such as clopidogrel.

Citation

Peng Foo Wong, Lee-Yee Chong, Gerard Stansby. Antiplatelet therapy to prevent cardiovascular events and mortality in patients with intermittent claudication. JAMA : the journal of the American Medical Association. 2013 Mar 6;309(9):926-7